123 related articles for article (PubMed ID: 38863976)
1. Chinese herbal medicine Shufeng Jiedu capsule for mild to moderate COVID-19: a multicenter, randomized, double-blind, placebo-controlled phase II trial.
Lu CL; Yang LQ; Jin XY; Friedemann T; Li YF; Liu XH; Chen XY; Zou XY; Zhang BR; Wang FX; Lin YL; Tang YM; Cao ML; Jiang YL; Gao YF; Liu K; Tao ZG; Robinson N; Schröder S; Liu JP; Lu HZ
Front Pharmacol; 2024; 15():1383831. PubMed ID: 38863976
[No Abstract] [Full Text] [Related]
2. Shufeng Jiedu capsule for acute exacerbation of chronic obstructive pulmonary disease: a protocol of multicentre, randomised, double-blind, placebo-controlled trial.
Xia R; Fei Y; Zhang L; Jie Z; Fan X; Dai M; Moore M; Willcox M; Hu X; Francis N; Liang C; Fei G; Liu J
BMJ Open; 2023 Sep; 13(9):e070864. PubMed ID: 37775286
[TBL] [Abstract][Full Text] [Related]
3. The add-on effect of Shufeng Jiedu capsule for treating COVID-19: A systematic review and meta-analysis.
Sheng X; Chen C; Jiang G; Ji Z; Guo Z; Hu H; Wang H; Zhai J; Zhang D; Zhang J; Guo L
Front Med (Lausanne); 2022; 9():1020286. PubMed ID: 36325392
[TBL] [Abstract][Full Text] [Related]
4. Chinese Patent Medicine Shufeng Jiedu Capsules as an Adjuvant Therapy for Community-Acquired Pneumonia: A Systematic Review and Meta-Analysis of Randomized Clinical Trials.
Zhang XW; Xia RY; Gao JQ; Liu JJ; Xu DH; Li X; Hu XY; Willcox M; Moore M; Dai MY; Trill J; Fei YT; Liu JP
Front Pharmacol; 2022; 13():923395. PubMed ID: 35860018
[No Abstract] [Full Text] [Related]
5. Shufeng Jiedu capsules for treating acute exacerbations of chronic obstructive pulmonary disease: a systematic review and meta-analysis.
Xia RY; Hu XY; Fei YT; Willcox M; Wen LZ; Yu MK; Zhang LS; Dai MY; Fei GH; Thomas M; Francis N; Wilkinson T; Moore M; Liu JP
BMC Complement Med Ther; 2020 May; 20(1):151. PubMed ID: 32448238
[TBL] [Abstract][Full Text] [Related]
6. Treating acute exacerbations of COPD with Chinese herbal medicine to aid antibiotic use reduction (Excalibur): a randomised double-blind, placebo-controlled feasibility trial.
Willcox ML; Hu XY; Oliver T; Thorne K; Boxall C; He G; Simpson C; Brotherwood B; O'Neil A; Waugh R; Tilt E; Trill J; Goward N; Francis N; Thomas M; Little P; Wilkinson T; Liu JP; Griffiths G; Moore M
Front Pharmacol; 2023; 14():1221905. PubMed ID: 37818189
[No Abstract] [Full Text] [Related]
7. Safety and Efficacy of Imatinib for Hospitalized Adults with COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Emadi A; Chua JV; Talwani R; Bentzen SM; Baddley J
Trials; 2020 Oct; 21(1):897. PubMed ID: 33115543
[TBL] [Abstract][Full Text] [Related]
8. Virtualized clinical studies to assess the natural history and impact of gut microbiome modulation in non-hospitalized patients with mild to moderate COVID-19 a randomized, open-label, prospective study with a parallel group study evaluating the physiologic effects of KB109 on gut microbiota structure and function: a structured summary of a study protocol for a randomized controlled study.
Haran JP; Pinero JC; Zheng Y; Palma NA; Wingertzahn M
Trials; 2021 Apr; 22(1):245. PubMed ID: 33810796
[TBL] [Abstract][Full Text] [Related]
9. Reconvalescent plasma/camostat mesylate in early SARS-CoV-2 Q-PCR positive high-risk individuals (RES-Q-HR): a structured summary of a study protocol for a randomized controlled trial.
Keitel V; Jensen B; Feldt T; Fischer JC; Bode JG; Matuschek C; Bölke E; Budach W; Plettenberg C; Scheckenbach K; Kindgen-Milles D; Timm J; Müller L; Kolbe H; Stöhr A; Calles C; Hippe A; Verde P; Spinner CD; Schneider J; Wolf T; Kern WV; Nattermann J; Zoufaly A; Ohmann C; Luedde T;
Trials; 2021 May; 22(1):343. PubMed ID: 34001215
[TBL] [Abstract][Full Text] [Related]
10. A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.
Akova M; Unal S
Trials; 2021 Apr; 22(1):276. PubMed ID: 33849629
[TBL] [Abstract][Full Text] [Related]
11. [Efficacy and safety of Regan Syrup in treatment of common cold (wind-heat syndrome):a multicenter, randomized, double-blind, double-dummy, placebo and positive drug-controlled, parallel, phase Ⅱb clinical trial].
Hu YM; Liu QQ; Chen S; Chen YY; Wang L; Liu N; Chen N; Long YY; Dong H
Zhongguo Zhong Yao Za Zhi; 2023 Apr; 48(8):2233-2240. PubMed ID: 37282911
[TBL] [Abstract][Full Text] [Related]
12. Exploration of the utility of different doses of Qingfei Dayuan granules: a multicenter, randomized, double-blind, placebo-controlled trial.
Zhu X; Li W; Yang Y; Li H; Yang M; Zhang J; Li X; Yan G; Wu X; Zhao W; Cui M; Yang X; Hu X; Huang J; Ba Y
Aging (Albany NY); 2024 Feb; 16(5):4503-4517. PubMed ID: 38412322
[TBL] [Abstract][Full Text] [Related]
13. Treating Acute EXacerbations of COPD with Chinese HerbAL MedIcine to aid AntiBiotic Use Reduction (EXCALIBUR): study protocol of a randomised double-blind, placebo-controlled feasibility trial.
Hu XY; Oliver T; Willcox M; Simpson C; Thorne K; Trill J; Francis N; Stuart B; Thomas M; Little P; Liu JP; Griffiths G; Moore M
Pilot Feasibility Stud; 2022 Dec; 8(1):262. PubMed ID: 36536462
[TBL] [Abstract][Full Text] [Related]
14. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
15. Chinese patent herbal medicine (Shufeng Jiedu capsule) for acute upper respiratory tract infections: A systematic review and meta-analysis.
Zhang YY; Xia RY; Liang SB; Hu XY; Dai MY; Li YL; Zhao LY; Moore M; Fei YT; Liu JP
Integr Med Res; 2021 Sep; 10(3):100726. PubMed ID: 33996460
[TBL] [Abstract][Full Text] [Related]
16. Testing the efficacy and safety of BIO101, for the prevention of respiratory deterioration, in patients with COVID-19 pneumonia (COVA study): a structured summary of a study protocol for a randomised controlled trial.
Dioh W; Chabane M; Tourette C; Azbekyan A; Morelot-Panzini C; Hajjar LA; Lins M; Nair GB; Whitehouse T; Mariani J; Latil M; Camelo S; Lafont R; Dilda PJ; Veillet S; Agus S
Trials; 2021 Jan; 22(1):42. PubMed ID: 33430924
[TBL] [Abstract][Full Text] [Related]
17. [Systematic review and Meta-analysis of efficacy and safety of Shufeng Jiedu Capsules in treatment of influenza].
Zhou F; Zhao GZ; Li B; Xu XL; Shi YF; Mao YY; Tian JH; Liu QQ
Zhongguo Zhong Yao Za Zhi; 2023 Nov; 48(22):6216-6224. PubMed ID: 38114228
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of Traditional Chinese Medicine, Maxingshigan-Weijing in the management of COVID-19 patients with severe acute respiratory syndrome: A structured summary of a study protocol for a randomized controlled trial.
Zeng C; Yuan Z; Pan X; Zhang J; Zhu J; Zhou F; Shan Z; Yuan Y; Ye R; Cheng J
Trials; 2020 Dec; 21(1):1029. PubMed ID: 33357239
[TBL] [Abstract][Full Text] [Related]
19. Hydroxychloroquine efficacy and safety in preventing SARS-CoV-2 infection and COVID-19 disease severity during pregnancy (COVID-Preg): a structured summary of a study protocol for a randomised placebo controlled trial.
González R; García-Otero L; Pons-Duran C; Marbán-Castro E; Goncé A; Llurba E; Gil MDM; Rodríguez-Zambrano MÁ; Chen H; Ramírez M; Bardají A; Menendez C
Trials; 2020 Jul; 21(1):607. PubMed ID: 32616063
[TBL] [Abstract][Full Text] [Related]
20. Safety and efficacy of inhaled IBIO123 for mild-to-moderate COVID-19: a randomised, double-blind, dose-ascending, placebo-controlled, phase 1/2 trial.
Maranda B; Labbé SM; Lurquin M; Brabant P; Fugère A; Larrivée JF; Grbic D; Leroux A; Leduc F; Finzi A; Gaudreau S; Swart Y;
Lancet Infect Dis; 2024 Jan; 24(1):25-35. PubMed ID: 37619584
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
